Age: 14.0
Sex: M
Vaccine: HPVX, MNQ
Symptoms: Medication error, No adverse event, Wrong product administered
Clinical narrative: prescribed a hpv vaccine, however the nurse thought the patient was supposed to receive medquadfi instead,with no reported adverse event; Initial information received on 19-Oct-2022 regarding an unsolicited valid non-serious case received from a healthcare professional.  This case involves a 14 year old male patient to whom prescribed a hpv vaccine, however the nurse thought the patient was supposed to receive MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] instead, with no reported adverse event.  The patient's past medical treatment included MENACTRA on 03-Dec-2020. The patient's past medical history, vaccination(s) and family history were not provided.  On 03-Dec-2020, the patient received dose 1 of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE (strength, formulation, dose, route: unknown) (lot number and expiry date: not reported) via intramuscular route in unknown administration site. On 17-Oct-2022 he also received a dose 2 of the same vaccine at 0.5ml dose (lot number: U7218AC and expiry date: 22-Feb-2024) via intramuscular route in the left deltoid for immunization.  On an unknown date, the patient received suspect HPV VACCINE not produced by Sanofi Pasteur (strength, formulation, route, dose: unknown) (lot number and expiry date: not reported) in unknown administration site for Prophylactic vaccination (Immunisation).  On 17-Oct-2022, developed a non-serious event of prescribed a hpv vaccine, however the nurse thought the patient was supposed to receive medquadfi instead, with no reported adverse event (wrong product administered; latency: 1 year 10 months 14 days) following the administration of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE and (unknown latency) following the administration of HPV VACCINE.  It was reported, Consumer had one dose of Menactra, and it is stating that consumer should get third dose Oct. 17, 2027. Consumer mother wanted clarification on any adverse events or anything else. The patient did not have any side effects as a result of this. The HCP asks if there are any safety reasons to be concerned about, if it is a valid dose, when the next dose of MEDQUADFI should be given. Referred caller to HPV manufacturer for any concerns about HPV vaccine. Product and Diluent Lot numbers: No diluent. Please see the Lot#/Exp date- How purchased: Distributor- Number of units affected: 1 unit - Is dose not used or not available: Used and available - Whether product is available for return: HCP is not requesting replacement -Information to be gathered on the type of needle that was used by the end-user (e.g. gauge size): McKesson 1 inch needle.  Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) and HPV VACCINE (HPV VACCINE) was not applicable.  At time of reporting, the outcome was Unknown.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.